Subbiah Tempers Concerns Regarding Pembrolizumab Approval in TMB-High Solid Tumors

In our exclusive interview, Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in tumor mutational burden–high solid tumors, shares the “transformative importance” of the regulatory decision, and speaks to the controversy surrounding the approval.